カテゴリ： GlobalData, アメリカ, 企業調査

ContraVir Pharmaceuticals Inc (CTRV)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：ContraVir Pharmaceuticals Inc (CTRV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8298
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：62
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
ContraVir Pharmaceuticals Inc (ContraVir) is a biopharmaceutical company that offers development and commercialization of targeted antiviral therapies. The company provides pipeline product such as TXL, potent prodrug of antiviral tenofovir and CRV431 cyclophilin inhibitor that increases its potency and selective index against HBV. It products are used for the treatment of chronic hepatitis B and shingles. ContraVir serves atients and healthcare professionals by developing differentiated therapeutic products. The company operates in the US. ContraVir is headquartered in Edison, New Jersey, the US.

ContraVir Pharmaceuticals Inc (CTRV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Ciclofilin Pharma Acquires NICAMs Assets from Aurinia Pharma 11
Venture Financing 12
Ciclofilin Pharma Raises USD0.05 Million in Venture Financing 12
Partnerships 13
ContraVir Pharma Enters into Agreement with Li Ka Shing Institute of Virology 13
Center Point Clinical Services Enters into Agreement with ContraVir Pharma 14
Licensing Agreements 15
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 15
Equity Offering 17
ContraVir Pharma to Raise USD10.8 Million Rights Offering of Shares 17
ContraVir Pharma Raises up to USD13.6 Million in Public Offering of Shares 18
ContraVir Pharma Raises USD7 Million in Public Offering of Shares and Warrants 19
ContraVir Pharma Raises USD15 Million in Public Offering of Shares and Warrants 20
ContraVir Pharma Raises USD9 Million in Private Placement of Preferred Shares 22
ContraVir Pharma Spin Off from Synergy Pharma 23
ContraVir Pharma Completes Private Placement Of Securities For US$3 Million 24
Debt Offering 25
ContraVir Pharma Raises USD3.3 Million in Private Placement of 10% Notes Due 2019 25
Acquisition 26
ContraVir Pharma Acquires Ciclofilin Pharma 26
ContraVir Pharmaceuticals Inc – Key Competitors 27
ContraVir Pharmaceuticals Inc – Key Employees 28
ContraVir Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Corporate Communications 30
Oct 03, 2018: ContraVir Pharmaceuticals names Robert Foster as acting Chief Executive Officer 30
Jun 20, 2018: ContraVir Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements 31
Apr 09, 2018: ContraVir Pharmaceuticals Appoints Two New Hepatitis B Experts to Scientific Advisory Board 32
Feb 05, 2018: Contravir Pharmaceuticals Receives Positive Nasdaq Listing Determination 33
Dec 29, 2017: ContraVir Pharmaceuticals Announces John Sullivan-Bolyai, M.D., MPH Steps Down as Chief Medical Officer 34
Product News 35
11/27/2017: ContraVir Pharmaceuticals to Make Presentation on CRV431 at HEP DART 2017 35
11/27/2017: ContraVir Pharmaceuticals to Make Presentations at HEP DART 2017 36
10/12/2017: ContraVir Pharmaceuticals to Present Poster on CMX-157 at AASLD 2017 and Participate in Search for HBV / HDV Cure Analyst Day 37
10/12/2017: ContraVir Pharmaceuticals to Present two Posters on CRV-431 at AASLD 2017 38
09/19/2017: ContraVir Pharmaceuticals Announces Participation at the Discovery on Target 2017 Conference in Boston 39
09/11/2017: ContraVir Pharmaceuticals Receives HBV IND Approval for Tenofovir Exalidex in the United States 40
09/06/2017: ContraVir Pharmaceuticals Announces Acceptance of Clinical Trial Application in the United Kingdom 41
05/04/2017: ContraVir to Advance Second-Generation Formulation of Tenofovir Exalidex for Treatment of Hepatitis B Virus 42
04/22/2017: Data Enhances Understanding of ContraVir’s Complementary Anti-HBV Compounds Tenofovir Exalidex and CRV431 43
04/12/2018: ContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress 44
04/11/2017: ContraVir to Highlight New Data on Tenofovir Exalidex at EASL The International Liver Congress 2017 in Amsterdam, The Netherlands 46
04/11/2017: ContraVir to Present Data on CRV431 at EASL The International Liver Congress 2017 in Amsterdam, The Netherlands 47
04/04/2017: ContraVir’s Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg) 48
04/03/2018: ContraVir Pharmaceuticals to Present On its HBV Drug Candidate CMX-157 at the 53rd Annual International Liver Congress 49
04/03/2018: ContraVir Pharmaceuticals to Present On its HBV Drug Candidate CRV-431 at the 53rd Annual International Liver Congress 50
01/03/2017: ContraVir Awarded Grant from Canada’s National Research Council to Advance CRV431 for the Treatment of Hepatitis B 51
Product Approvals 52
Feb 22, 2018: ContraVir Pharmaceuticals Announces TXL Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population 52
Feb 12, 2018: ContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL Leveraging the 505(b)(2) Regulatory Pathway 53
Clinical Trials 54
Feb 06, 2018: ContraVir Pharmaceuticals Completes Renal Impairment Study with TXL 54
Oct 24, 2017: ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431 55
Oct 19, 2017: ContraVir Pharmaceuticals Initiated Dosing of Renally-Impaired Patients in First U.S. Trial with TXL 56
Aug 08, 2017: ContraVir Pharmaceuticals Selected to Present Poster on TXL at the Upcoming AASLD Meeting 2017 57
Aug 03, 2017: ContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at the Upcoming AASLD Meeting 2017 58
Apr 20, 2017: Oral Presentation at EASL Highlights ContraVir’s Tenofovir Exalidex Antiviral Activity in Hepatitis B Patients 59
Feb 14, 2017: ContraVir to Highlight Clinical Data from Ongoing Phase 2a Study of Tenofovir Exalidex for Treating Hepatitis B 60
Other Significant Developments 61
Aug 06, 2018: Contravir Pharmaceuticals provides an update to corporate objective 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraVir Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ciclofilin Pharma Acquires NICAMs Assets from Aurinia Pharma 11
Ciclofilin Pharma Raises USD0.05 Million in Venture Financing 12
ContraVir Pharma Enters into Agreement with Li Ka Shing Institute of Virology 13
Center Point Clinical Services Enters into Agreement with ContraVir Pharma 14
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 15
ContraVir Pharma to Raise USD10.8 Million Rights Offering of Shares 17
ContraVir Pharma Raises up to USD13.6 Million in Public Offering of Shares 18
ContraVir Pharma Raises USD7 Million in Public Offering of Shares and Warrants 19
ContraVir Pharma Raises USD15 Million in Public Offering of Shares and Warrants 20
ContraVir Pharma Raises USD9 Million in Private Placement of Preferred Shares 22
ContraVir Pharma Spin Off from Synergy Pharma 23
ContraVir Pharma Completes Private Placement Of Securities For US$3 Million 24
ContraVir Pharma Raises USD3.3 Million in Private Placement of 10% Notes Due 2019 25
ContraVir Pharma Acquires Ciclofilin Pharma 26
ContraVir Pharmaceuticals Inc, Key Competitors 27
ContraVir Pharmaceuticals Inc, Key Employees 28
ContraVir Pharmaceuticals Inc, Other Locations 29
ContraVir Pharmaceuticals Inc, Subsidiaries 29

List of Figures
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ContraVir Pharmaceuticals Inc (CTRV)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Henry Schein Inc (HSIC)：企業の財務・戦略的SWOT分析
    Henry Schein Inc (HSIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Maxim Power Corp. (MXG)：企業の財務・戦略的SWOT分析
    Maxim Power Corp. (MXG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • QIC Ltd：企業の戦略・SWOT・財務情報
    QIC Ltd - Strategy, SWOT and Corporate Finance Report Summary QIC Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Sobha Ltd：企業の戦略・SWOT・財務情報
    Sobha Ltd - Strategy, SWOT and Corporate Finance Report Summary Sobha Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • China Pioneer Pharma Holdings Ltd (1345)：企業の財務・戦略的SWOT分析
    Summary China Pioneer Pharma Holdings Ltd (Pioneer Pharma) is an investment holding company that markets and promotes pharmaceutical products and medical devices. The company offers pharmaceutical products such as anti-inflammatory medicines, pain management, orthopedics, opthalmology, chronic obstr …
  • LivaNova PLC (LIVN)：企業の財務・戦略的SWOT分析
    LivaNova PLC (LIVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Department of Defense Education Activity：企業の戦略的SWOT分析
    Department of Defense Education Activity - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Hellenic Telecommunications Organization SA (HTO)：企業の財務・戦略的SWOT分析
    Hellenic Telecommunications Organization SA (HTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Cost Plus Inc：企業の戦略的SWOT分析
    Cost Plus Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Xero Ltd (XRO)：企業の財務・戦略的SWOT分析
    Xero Ltd (XRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Eutelsat Communications S.A. (ETL)：企業の財務・戦略的SWOT分析
    Eutelsat Communications S.A. (ETL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • EDAP TMS SA (EDAP)：医療機器：M&Aディール及び事業提携情報
    Summary EDAP TMS SA (EDAP) is a medical device company. It carries out the development, production and distribution of minimally invasive medical devices for the treatment of urological diseases. It offers High Intensity Focused Ultrasound (HIFU) devices for the treatment of localized prostate cance …
  • Close Brothers Group Plc：企業の戦略・SWOT・財務分析
    Close Brothers Group Plc - Strategy, SWOT and Corporate Finance Report Summary Close Brothers Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Orpea SA (ORP)：企業の財務・戦略的SWOT分析
    Summary Orpea SA (Orpea) is a healthcare consulting company that offers clinical care services. The company provides services such as suite care clinic services, retirement homes, and mental hospital services, among others. Its mental hospital services include treatment of mood disorders, overuse sy …
  • Angelo Iafrate Construction Company：企業の戦略・SWOT・財務分析
    Angelo Iafrate Construction Company - Strategy, SWOT and Corporate Finance Report Summary Angelo Iafrate Construction Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Cubic Corp (CUB)：企業の財務・戦略的SWOT分析
    Cubic Corp (CUB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • E-CO Energi Holding AS-エネルギー分野：企業M&A・提携分析
    Summary E-CO Energi Holding AS (E-CO Energi) owned by the City of Oslo is an energy company. It owns, operates and develops hydroelectric plants. The company is the second largest hydropower producer in Norway. E-CO Energi also carries out the business development in energy and related fields. The c …
  • Otsuka Pharmaceutical Co Ltd：医療機器：M&Aディール及び事業提携情報
    Summary Otsuka Pharmaceutical Co Ltd (OPC), a subsidiary of Otsuka Holdings Co Ltd is a provider of healthcare products. The company offers products which include pocari sweat, pocari sweat ion water, oronamin c, calorie mate, nature made, jerubure, jarinea, five mini, amino-value, enerugen, jog mat …
  • Pfenex Inc (PFNX)：企業の財務・戦略的SWOT分析
    Summary Pfenex Inc (Pfenex) is a biologics company that develops biosimilar therapeutics. The company’s lead product candidate includes, PF582, a biosimilar candidate which is used for the treatment of retinal diseases. It also develops PF530, a biosimilar candidate for the treatment of multiple scl …
  • Yapi Merkezi Holding Inc.
    Yapi Merkezi Holding Inc. - Strategy, SWOT and Corporate Finance Report Summary Yapi Merkezi Holding Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆